Comparative Pharmacology
Head-to-head clinical analysis: LUMIGAN versus TRAVATAN Z.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LUMIGAN versus TRAVATAN Z.
LUMIGAN vs TRAVATAN Z
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Bimatoprost is a prostamide analog that selectively mimics the effects of prostamide F2α, activating prostaglandin F (FP) receptors. It increases aqueous humor outflow through the uveoscleral pathway and may also enhance trabecular outflow, reducing intraocular pressure.
Selective FP prostanoid receptor agonist; increases uveoscleral outflow of aqueous humor by binding to FP receptors in the ciliary muscle and trabecular meshwork, leading to matrix metalloproteinase activation and remodeling of extracellular matrix.
One drop of 0.01% ophthalmic solution in the affected eye(s) once daily in the evening.
One drop in the affected eye(s) once daily in the evening. Ophthalmic solution 0.004% (travoprost 0.04 mg/mL).
None Documented
None Documented
Terminal elimination half-life is approximately 78 minutes (range 54-102 minutes) in plasma after ocular administration. This short half-life reflects rapid systemic clearance, but ocular tissue levels persist longer due to local tissue binding.
Terminal elimination half-life is 45 minutes; due to rapid hydrolysis to active acid, the clinical effect duration is longer than the half-life suggests.
Primarily via renal elimination (approximately 67% of administered dose excreted in urine as metabolites, with less than 1% as unchanged drug). The remainder is excreted in feces (approx. 25%) via biliary elimination.
Primarily eliminated via hepatic metabolism; renal excretion of metabolites accounts for approximately 20% of the dose; fecal excretion is minimal.
Category C
Category C
Prostaglandin Analog
Prostaglandin Analog